Medicine & Healthcare

Impotence or erectile dysfunction is one of the most commonly experienced sexual problems amongst men.One of the most effective and popular prescription medications used by men for treating erectile dysfunction is Cialis. This pill is also known as 'the weekend pill' as its effectiveness lasts for up to 36 hours after taking the pill.

The frequency with which scientists fabricate and falsify data, or commit other forms of scientific misconduct is a matter of controversy... Misconduct was reported more frequently by medical/pharmacological researchers than others...This metareview is a conservative estimate of the true prevalence of scientific misconduct.

WikiProject Pharmacology coordinates the development of Wikipedia articles relating to drugs and pharmacology. Of interest to authors and editors of pharmacology articles.

Daily intake of fruit and vegetables was associated with a lower risk of coronary heart disease when combined with a high dairy fat consumption...but not when combined with a low dairy fat consumption. Sara Holmberg, Anders Thelin and Eva-Lena Stiernström. Int. J. Environ. Res. Public Health 2009, 6, 2626-2638.

Downloadable slideshows from this November 2007 conference. For report PDFs: (1) http://is.gd/3AoNu (2) http://is.gd/3AoXG

79% of patients had no evidence of their sBCC at two years after finishing treatment.

Superficial Basal Cell Carcinoma Aldara™ cream is indicated for the topical treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults, with a maximum tumor diameter of 2.0 cm, located on the trunk (excluding anogenital skin), neck, extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured.  The histological diagnosis of superficial basal cell carcinoma should be established for other types of basal cell carcinomas, including nodular, morpheaform (fibrosing or sclerosing) types.

PDF, Free full text article... We found that 5% imiquimod cream is aneffective treatment option for superficial and nodularbasal cell carcinomas, giving a clearance rate of89.5% at an average of 39 months of follow up.   Dr Yin Vun, Siller Medical, 9th Floor, SilvertonPlace, 101 Wickham Terrace, Brisbane, Qld 4000, Australia.

NoBlood website version of PubMed article...

Eight of nine individuals, 89% (95% CI 56% to 97%) were histologically clear of sBCC at 52 weeks.

Aldara® can eradicate 64% of low-risk nodular basal cell carcinomas.

Liver disease can decrease clearance of activated coagulation factors...It is often difficult to differentiate DIC from liver disease as cause of coagulation disorders...

Mohs surgery technique is is typically reserved for skin cancers that have a high risk of reappearing or for skin cancers that have recurred. Mohs surgery is also a preferred option for removing skin cancer from areas such as the face

FDA-approval:  * Biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults; maximum tumor diameter of 2.0 cm on trunk, neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured (1.2)

Lupus anticoagulant (LAC) increases risk for thrombotic complications...

There is reasonable evidence that the use of imiquimod for small (<2 cm) superficial BCC that occur other than on the face provides outcomes only marginally less satisfactory than surgery. There would be a place for imiquimod in treating patients with frequent multiple primary lesions when access to surgery is difficult or where clinical judgment may be influenced by patient factors as reported in some of the studies, eg, where patients may have contraindications to surgery.  It was noted that if recurrences occurred in this study they mostly occurred during the first 9 months after the end of treatment. The initial response was therefore predictive of long-term outcome so these authors recommend and encourage continued monitoring of skin lesions.

Raasch B. Clinical, Cosmetic and Investigational Dermatology. 9 June 2009.  There is reasonable evidence that the use of imiquimod for small (<2 cm) superficial BCC that occur other than on the face provides  outcomes only marginally less satisfactory t

Nodulo-cystic BCC. [Image, Photograph] Venura Samarasinghe, et al. J Skin Cancer. 2011;2011:328615.

The proportion of subjects who were clinically clear at the 2-year follow-up visit was estimated to be 82.0%. Imiquimod was tolerated when applied daily, with erythema reported for all subjects participating in the study. The recurrence rate observed suggests that once daily dosing and 5x/week dosing yield similar clearance rates, but daily dosing increases local skin reactions.

Clinical clearance rate at 1, 2 and 3 years were 94, 76 and 70%, respectively. We conclude that imiquimod seems to be an appropriate therapeutic alternative for the treatment of recurrent BCC in patients with associated co-morbidities.